Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Spinal cord injury (SCI) is a severe neurological disorder that significantly impacts patients' quality of life. Following SCI, the blood-spinal cord barrier (BSCB) is destroyed, leading to ischemia and hypoxia, which further exacerbates the imbalance in the spinal cord microenvironment. A2-type astrocytes, which arise under ischemic and hypoxic conditions, have been reported to promote SCI repair. However, the roles of exosomes derived from A2 astrocytes (A2-Exos) in SCI have not been explored. This study aims to investigate the role of A2-Exos in SCI repair, particularly in BSCB restoration, and to elucidate its potential mechanisms. GEO database analysis, western blotting, and immunofluorescence were used to detect A2 astrocyte polarization after SCI in mice. In vitro, A2 astrocytes were obtained through hypoxia induction, and A2-Exos were extracted via ultracentrifugation. An in vivo SCI model and a series of in vitro experiments demonstrated the reparative effects of A2-Exos on BSCB following SCI. Furthermore, miRNA sequencing analysis and rescue experiments confirmed the role of miRNAs in A2-Exos-mediated BSCB repair. Finally, luciferase assays and western blotting were performed to investigate the underlying mechanisms. The results showed that A2-Exos promote motor function recovery and BSCB repair in mice following SCI. In vitro, A2-Exos facilitated BSCB reconstruction and endothelial cell autophagy. miRNA sequencing identified miR-5121 as the most significantly enriched miRNA in A2-Exos, suggesting its involvement in BSCB repair and autophagy regulation. AKT2 was identified as a potential downstream target of miR-5121. Functional gain- and loss-of-function experiments further validated the miR-5121/AKT2 axis. Finally, we demonstrated that the AKT2/mTOR/p70S6K pathway may mediate the effects of miR-5121 in A2-Exos on BSCB repair.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998472PMC
http://dx.doi.org/10.1186/s12951-025-03365-3DOI Listing

Publication Analysis

Top Keywords

bscb repair
20
sci
10
bscb
9
spinal cord
8
sci repair
8
a2-exos
8
a2-exos sci
8
western blotting
8
a2-exos bscb
8
mirna sequencing
8

Similar Publications

Spinal cord injury (SCI) is a severe, disabling condition for which current treatments are largely insufficient in restoring neurological function. Despite advances in surgical and pharmacological interventions, no effective treatment currently exists to reverse neurological deficits caused by SCI. Mesenchymal stem cells (MSCs), especially human umbilical cord-derived MSCs (hucMSCs), have shown promise in tissue regeneration due to their multipotency and low immunogenicity.

View Article and Find Full Text PDF

A proactive cholinergic-like acidic fibroblast growth factor delivery system for efficient protein enrichment and native drug release in the central nervous system to promote repair of injured spinal cord.

Biomaterials

August 2025

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China; Cixi Biomedical Researc

Spinal cord injury (SCI) is a severe neurological trauma resulting in sensory deficits, impaired motor function, and compromised autonomic regulation. Acidic fibroblast growth factor (aFGF) with neuroprotective properties holds significant promise for promoting SCI repair. However, challenges of aFGF related to short blood circulation time, susceptibility to degradation, and severely restricted ability to cross blood-spinal cord barrier (BSCB) have hindered further exploration and utilization in SCI.

View Article and Find Full Text PDF

The complex etiology of neurological disorders is a major challenge to the identification of therapeutic candidates. Tackling brain vascular dysfunction is gaining attention from the scientific community, neurologists and pharmaceutical companies, as a novel disease-modifying strategy. Here, we provide evidence that at least 41% of neurological diseases and related conditions/injuries display a co-pathology of blood-brain and blood-spinal cord barrier alterations and dysfunctions, and we discuss why this figure may represent only a fraction of a larger phenomenon.

View Article and Find Full Text PDF

Background: Destruction of the blood-spinal cord barrier (BSCB) following spinal cord injury (SCI) can result in various harmful cytokines, neutrophils, and macrophages infiltrating into the injured site, causing secondary damage. Growing evidence shows that M2 macrophages and their small extracellular vesicles (sEVs) contribute to tissue repair in various diseases.

Methods And Results: In our previous proteomics-based analysis of protein expression profiles in M2 macrophages and their sEVs (M2-sEVs), the proteoglycan perlecan, encoded by HSPG2, was found to be upregulated in M2-sEVs.

View Article and Find Full Text PDF

Dimethyloxalylglycine improves functional recovery through inhibiting cell apoptosis and enhancing blood-spinal cord barrier repair after spinal cord injury.

Chin J Traumatol

March 2025

Molecular Pharmacology Research Center, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang province, China. Electronic address:

Purpose: The secondary damage of spinal cord injury (SCI) starts from the collapse of the blood spinal cord barrier (BSCB) to chronic and devastating neurological deficits. Thereby, the retention of the integrity and permeability of BSCB is well-recognized as one of the major therapies to promote functional recovery after SCI. Previous studies have demonstrated activation of hypoxia inducible factor-1α (HIF-1α) provides anti-apoptosis and neuroprotection in SCI.

View Article and Find Full Text PDF